BioSpace News Archive

Scientific Industries, Inc., a life sciences tool provider, and a developer and provider of digitally simplified bioprocessing and pharmacy automation products, announced the release of its newly redesigned VIVID® automated pill counter.

The Lupus Research Alliance, the world’s leading private funder of lupus research, announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.

Apellis Pharmaceuticals, Inc. and Sobi® reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety profile of EMPAVELI®/Aspaveli® for paroxysmal nocturnal hemoglobinuria.

Keros Therapeutics, Inc. announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes, as well as preclinical data on the differentiated mechanism of action of KER-050 and its activity on multiple stages of thrombopoiesis, at the 27th Annual Congress of the European Hematology Association, held in person and virtually June 9 through 17, 2022.

Amarin Corporation plc announces that the UK’s National Institute for Health and Care Excellence is recommending icosapent ethyl for reimbursement and use across the National Health Service in England and Wales to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides, LDL-C levels >1.04 mmol/L and established cardiovascular disease, at a price of £144.21 per 120 soft capsules.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress.

Trevena, Inc. announced that Carrie Bourdow, President & CEO, and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 - 16, 2022.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to cancer and infections, today shared that partner GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial evaluating their investigational RSV vaccine in adults aged 60 years and above.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799).

Stem cells give rise to all other cells and tissues with specialized functions, through a process called “differentiation,” in which stem cells divide to form daughter cells.